Differential modulatory effects of clarithromycin on the production of cytokines by a tumor.
In vitro treatment with clarithromycin inhibited the expression of the matrix metalloproteinase-9, transforming growth factor beta, and tumor necrosis factor alpha genes in 13762NF rat mammary adenocarcinoma cells. Transient enhancement, rather than inhibition, was observed for the interleukin-6 gene, and no significant change was observed for the tissue inhibitor of metalloproteinase-2 gene. Such an effect was not observed for cefotiam or gentamicin.
Sassa
K
K
First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Toyama 930-0152, Japan.
Mizushima
Y
Y
Kobayashi
M
M
D000230:Adenocarcinoma / Q000378:metabolism*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017291:Clarithromycin / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis*; D003864:Depression, Chemical; D005780:Gelatin / Q000378:metabolism; D015850:Interleukin-6 / Q000235:genetics; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D012313:RNA / Q000096:biosynthesis; D051381:Rats; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000096:biosynthesis / Q000235:genetics; D016212:Transforming Growth Factor beta / Q000096:biosynthesis; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D016207:Cytokines; D015850:Interleukin-6; D011500:Protein Synthesis Inhibitors; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D019716:Tissue Inhibitor of Metalloproteinase-2; D012313:RNA; D005780:Gelatin; D020780:Matrix Metalloproteinase 9; D017291:Clarithromycin